Related references
Note: Only part of the references are listed.9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2022
DIABETES CARE (2022)
Advancing therapy with iGlarLixi versus premix BIAsp 30 in basal insulin-treated type 2 diabetes: Design and baseline characteristics of the SoliMix randomized controlled trial
Rory J. McCrimmon et al.
DIABETES OBESITY & METABOLISM (2021)
Advancing Therapy in Suboptimally Controlled Basal Insulin-Treated Type 2 Diabetes: Clinical Outcomes With iGlarLixi Versus Premix BIAsp 30 in the SoliMix Randomized Controlled Trial
Julio Rosenstock et al.
DIABETES CARE (2021)
Switching to iGlarLixi Versus Continuing Daily or Weekly GLP-1 RA in Type 2 Diabetes Inadequately Controlled by GLP-1 RA and Oral Antihyperglycemic Therapy: The LixiLan-G Randomized Clinical Trial
Lawrence Blonde et al.
DIABETES CARE (2019)
Basal Insulin Intensification in Patients with Type 2 Diabetes: A Review
Jerry Meece
DIABETES THERAPY (2018)
Basal Insulin Intensification in Patients with Type 2 Diabetes: A Review
Jerry Meece
DIABETES THERAPY (2018)
Identification of barriers to insulin therapy and approaches to overcoming them
David Russell-Jones et al.
DIABETES OBESITY & METABOLISM (2018)
Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial
Julio Rosenstock et al.
DIABETES CARE (2016)
Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial
Vanita R. Aroda et al.
DIABETES CARE (2016)
Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors
William H. Polonsky et al.
PATIENT PREFERENCE AND ADHERENCE (2016)
Effects of the GLP-1 receptor agonist lixisenatide on postprandial glucose and gastric emptying - preclinical evidence
Ulrich Werner
JOURNAL OF DIABETES AND ITS COMPLICATIONS (2014)
Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study
M. Peyrot et al.
DIABETIC MEDICINE (2012)
Persistency of response to omalizumab therapy in severe allergic (IgE-mediated) asthma
J. Bousquet et al.
ALLERGY (2011)
Examining the ability to detect change using the TRIM-Diabetes and TRIM-Diabetes Device measures
Meryl Brod et al.
QUALITY OF LIFE RESEARCH (2011)
Correlates of Insulin Injection Omission
Mark Peyrot et al.
DIABETES CARE (2010)
Understanding and assessing the impact of treatment in diabetes: the Treatment-Related Impact Measures for Diabetes and Devices (TRIM-Diabetes and TRIM-Diabetes Device)
Meryl Brod et al.
HEALTH AND QUALITY OF LIFE OUTCOMES (2009)
How to Select, Calculate, and Interpret Effect Sizes
Joseph A. Durlak
JOURNAL OF PEDIATRIC PSYCHOLOGY (2009)
BRIEF REPORT: The burden of diabetes therapy - Implications for the design of effective patient-centered treatment regimens
S Vijan et al.
JOURNAL OF GENERAL INTERNAL MEDICINE (2005)
Share Paper
